Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Market Cap
$1.38B
P/E Ratio
2.92
1Y Stock Return
169.81%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
8.1
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the pricing of its previously announced underwritten public offering of 7,275,000 shares of its common stock at a price to the public of $27.50 per share. The agg
Yahoo
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investo
Finnhub
WALTHAM - Spyre Therapeutics, Inc. , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to...
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced positive interim Phase 1 data from its first-in-human trial of SPY001, an investigational novel, extended half-life monoclonal antibody targeting α4β7. SPY001 was
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a
Yahoo
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced its third quarter 2024 financial results and provided program and corporate updates.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
COR | -15.71% | $47.48B | +21.20% | 0.86% |
BTCT | -12.00% | $42.61M | +353.33% | 0.00% |
HUSA | -10.78% | $16.69M | -11.56% | 0.00% |
PULM | -10.11% | $19.83M | +202.98% | 0.00% |
KDP | -8.55% | $42.76B | -1.22% | 2.77% |
KNOP | -6.83% | $210.40M | +11.75% | 1.68% |
OXBR | -6.54% | $19.05M | +178.18% | 0.00% |
SUN | -6.30% | $7.32B | +1.51% | 6.47% |
GPRK | -6.11% | $440.00M | -9.95% | 6.37% |
PEP | -6.04% | $215.02B | -6.60% | 3.35% |
CBOE | -5.94% | $21.46B | +15.84% | 1.11% |
UUU | -5.59% | $4.97M | -41.89% | 0.00% |
TH | -5.50% | $839.02M | -24.49% | 0.00% |
BKNG | -5.35% | $164.72B | +58.25% | 0.53% |
BEST | -5.32% | $31.65M | +3.88% | 0.00% |
BCAN | -4.46% | $72.87M | -99.75% | 0.00% |
TPST | -4.43% | $37.75M | -77.59% | 0.00% |
FF | -4.05% | $227.57M | +21.57% | 4.55% |
MVO | -4.05% | $106.15M | -22.78% | 16.78% |
MNOV | -3.95% | $93.19M | +2.15% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GPRO | 35.10% | $179.52M | -67.23% | 0.00% |
MGTX | 33.41% | $467.36M | +9.12% | 0.00% |
BHVN | 33.00% | $4.67B | +56.79% | 0.00% |
SSTK | 31.85% | $1.03B | -34.23% | 3.95% |
LAB | 31.80% | $562.11M | -34.35% | 0.00% |
OVID | 31.25% | $73.14M | -68.60% | 0.00% |
ALLO | 30.87% | $444.50M | -24.82% | 0.00% |
SWTX | 30.71% | $2.82B | +79.34% | 0.00% |
CLRB | 30.28% | $65.31M | -24.77% | 0.00% |
OPEN | 30.19% | $1.14B | -31.62% | 0.00% |
QTRX | 30.01% | $424.47M | -53.12% | 0.00% |
SIL | 30.00% | $1.55B | +88.25% | 0.00% |
ESRT | 29.55% | $1.82B | +25.43% | 1.29% |
PGRE | 29.55% | $1.04B | +5.31% | 2.23% |
SPCE | 29.47% | $196.64M | -84.01% | 0.00% |
CRDF | 29.41% | $133.97M | +127.83% | 0.00% |
DNTH | 29.35% | $659.13M | +93.65% | 0.00% |
SLRC | 29.34% | - | - | 10.00% |
NVCR | 29.19% | $1.78B | +34.75% | 0.00% |
APLS | 28.97% | $3.61B | -41.27% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LFVN | <0.01% | $169.84M | +130.61% | 1.10% |
ALAR | <0.01% | $89.09M | +158.08% | 0.00% |
POWL | -0.03% | $3.74B | +275.35% | 0.29% |
CORZ | -0.11% | $4.60B | +3,201.26% | 0.00% |
NSSC | -0.12% | $1.33B | +26.57% | 1.12% |
LQDA | 0.20% | $859.91M | +53.94% | 0.00% |
IMNN | -0.20% | $10.02M | -22.89% | 0.00% |
STG | -0.22% | $35.67M | +7.92% | 0.00% |
DOOO | 0.23% | $3.55B | -33.66% | 1.24% |
CANG | 0.24% | $253.50M | +212.50% | 0.00% |
NTZ | 0.24% | $47.64M | -30.94% | 0.00% |
FCN | -0.27% | $7.10B | -10.74% | 0.00% |
LUMO | 0.28% | $37.45M | +41.97% | 0.00% |
YUM | 0.30% | $36.88B | +3.04% | 1.98% |
ACGL | -0.34% | $36.00B | +16.84% | 0.00% |
MAGN | 0.35% | $638.97M | -3.42% | 0.00% |
CASI | -0.36% | $71.56M | -6.32% | 0.00% |
NAT | 0.37% | $636.83M | -30.05% | 13.79% |
QD | 0.38% | $335.92M | +42.44% | 0.00% |
SSTI | -0.39% | $148.04M | -50.92% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZ | 0.01% | $708.37M | 0.2% |
SPTS | 0.06% | $5.71B | 0.03% |
CANE | 0.13% | $17.72M | 0.29% |
XMPT | -0.20% | $230.08M | 1.98% |
AGGH | 0.59% | $253.02M | 0.33% |
SHV | -0.72% | $18.13B | 0.15% |
HYMB | 1.09% | $2.81B | 0.35% |
DBA | 1.10% | $755.88M | 0.93% |
ULST | 1.13% | $535.47M | 0.2% |
PREF | 1.22% | $999.92M | 0.55% |
UCON | 1.22% | $3.19B | 0.85% |
JPST | 1.36% | $28.43B | 0.18% |
JBBB | 1.40% | $1.26B | 0.49% |
VGSH | 1.40% | $19.14B | 0.04% |
CGSM | 1.47% | $514.53M | 0.25% |
HYEM | 1.51% | $408.28M | 0.4% |
BILZ | -1.57% | $563.02M | 0.14% |
HIGH | 1.57% | $302.78M | 0.51% |
IBDQ | 1.60% | $2.89B | 0.1% |
VUSB | 1.67% | $4.64B | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 47.66% | $273.87M | 0% |
QQA | 47.42% | $135.01M | 0% |
XBI | 38.44% | $6.58B | 0.35% |
EFAA | 38.01% | $117.38M | 0% |
IBB | 35.98% | $6.66B | 0.45% |
RYLD | 35.03% | $1.45B | 0.6% |
PBE | 34.84% | $258.53M | 0.58% |
IWC | 33.91% | $933.99M | 0.6% |
VBK | 33.43% | $19.31B | 0.07% |
VXF | 33.07% | $21.54B | 0.06% |
IWO | 32.96% | $12.56B | 0.24% |
KOMP | 32.92% | $2.09B | 0.2% |
XPH | 32.72% | $157.87M | 0.35% |
IVAL | 32.61% | $140.99M | 0.39% |
TMSL | 32.51% | $288.12M | 0.55% |
SMMD | 32.42% | $1.24B | 0.15% |
VTWO | 32.36% | $12.38B | 0.1% |
GNOM | 32.36% | $70.59M | 0.5% |
FINX | 32.30% | $332.34M | 0.68% |
ARKF | 32.16% | $1.09B | 0.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -22.17% | $388.04M | 1.43% |
VIXY | -20.20% | $195.31M | 0.85% |
EQLS | -12.34% | $76.08M | 1% |
TAIL | -11.45% | $67.98M | 0.59% |
USDU | -10.45% | $201.97M | 0.5% |
DBE | -10.29% | $50.13M | 0.77% |
DBO | -8.76% | $217.57M | 0.77% |
UUP | -8.50% | $309.25M | 0.77% |
COMT | -7.58% | $829.06M | 0.48% |
XHLF | -6.62% | $874.27M | 0.03% |
KCCA | -6.56% | $220.51M | 0.87% |
HDRO | -6.33% | $164.26M | 0.3% |
CTA | -6.13% | $350.27M | 0.78% |
TBIL | -5.95% | $4.38B | 0.15% |
KMLM | -5.86% | $353.87M | 0.9% |
AGZD | -4.85% | $142.76M | 0.23% |
XBIL | -3.33% | $637.70M | 0.15% |
WEAT | -3.13% | $120.27M | 0.28% |
XONE | -2.15% | $548.88M | 0.03% |
IBTF | -2.13% | $2.05B | 0.07% |
Current Value
$26.861 Year Return
Current Value
$26.861 Year Return